Abstract:Objectives To establish a mouse model of persistent tuberculosis involving Mycobacterium tuberculosis with different levels of virulence and to study the characteristics of that infection in order to lay a new foundation for the assessment and study of new vaccines and drugs against tuberculosis.Methods Female BALB/c mice were intravenously infected via the tail vein with 5 × 104 colony-forming units (CFUs) of the H37Rv standard virulent strain,the H37Ra strain,or the BCG vaccine strain of M.tuberculosis.Four and 8 weeks after infection,changes in the general status of mice and their weight were observed.Samples of lung and spleen tissues from infected mice were collected for histopathologic examination after HE staining.Mouse sera were tested for the titer of antibodies against M.tuberculosis using ELISA.Splenic lymphocytes of infected mice were isolated for an MTS assay of lymphocyte proliferation,and Th1/Th2 cytokines were detected with ELISA.The bacterial load in the spleen and lungs was determined by counting colony-forming units (CFUs) on 7H10 plates.Results There were no significant differences in the weight of mice 8 weeks after infection with strains that had differing levels of virulence.Macroscopic splenomegaly was observed in mice infected with H37Rv.Pathological lesions occurred in all infected mice according to histopathological slices.Four weeks after infection,Mycobacterium-specific antibodies were detected,and the antibody titer in infected mice did not differ significantly.The proliferation of spleen lymphocytes and the production of Th1/Th2 cytokines increased significantly in mice infected with H37Ra and mice infected with H37Rv.Four weeks after infection,the production of IFN-γ and IL-10 increased significantly in mice infected with H37Rv (P＜0.05).The bacterial load in the spleen of mice infected with H37Rv increased to 4.389±0.1245 log10 CFU,which was significantly higher than the load in mice infected with BCG (P＜0.05).The bacterial load in mice infected with H37Ra was 4.068±0.2184 log10 CFU,but the load did not differ significantly between mice infected with H37Ra and mice infected with BCG.There were no differences in the bacterial load in the lungs of the 3 infected groups.Eight weeks after infection,the bacterial load in the spleen of mice infected with H37Ra and mice infected with H37Rv increased significantly in comparison to that in mice infected with BCG (P＜0.05),but the bacterial load in the lungs did not differ among the 3 groups.The bacterial load in organs remained the same for at least 8 weeks,indicating a persistent infection.Conclusion A mouse model of persistent tuberculosis was successfully established and the characteristics of that infection were studied.This work will provide a useful animal model for further research and development of new vaccines and drugs against tuberculosis.

The Multistate Tuberculosis Pharmacometric Model: a Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model for Studying Drug Effects in an Acute Tuberculosis Mouse Model

Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model

Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models

Establishment of a mouse model of infection with rifampicin-resistant Mycobacterium tuberculosis

Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis

A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations

Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis

The use of Mycobacterium tuberculosis H37Ra-infected immunocompetent mice as an in vivo model of persisters

Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling

Pharmacokinetic–pharmacodynamic modeling of tuberculosis time to positivity and colony-forming unit to assess the response to dose-ranging linezolid

A minimal PBPK model to accelerate preclinical development of drugs against tuberculosis

Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures

One Size Fits All? Not in in Vivo Modeling of Tuberculosis Chemotherapeutics

Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice

Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical species to humans using PBPK modelling

Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling

Establishment of a mouse model for Mycobacterium tuberculosis persistent infection and its immunological characteristics

Mycobacterium Tuberculosis Carrying a Rifampicin Drug Resistance Mutation Reprograms Macrophage Metabolism Through Cell Wall Lipid Changes

Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse.

Establishment of mouse models of persistent tuberculosis and characteristics of that infection

Quantitative Systems Pharmacology Modeling Framework of Autophagy in Tuberculosis: Application to Adjunctive Metformin Host-Directed Therapy